Physician profile
Thomas J Joly
NPI 1093709156
$95,209.78
in general payments reported to CMS, 2019-2025
33 companies · $26K in 2025
The $26K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $1,901 · 2021: $7,417 · 2022: $20K · 2023: $20K · 2024: $19K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Honoraria: $18K · Consulting Fee: $6,300 · Food and Beverage: $5,326 · Travel and Lodging: $3,465 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,287.50 |
| Honoraria | $17,800.00 |
| Consulting Fee | $6,300.00 |
| Food and Beverage | $5,326.21 |
| Travel and Lodging | $3,464.70 |
| Education | $110.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $47,989.27 | 2019-2023 | Tepezza, Uplizna |
| Amgen INC. | $44,226.05 | 2024-2025 | Tepezza |
| Mallinckrodt Hospital Products INC. | $846.98 | 2020-2025 | Acthar |
| New World Medical,INC. | $237.94 | 2023 | |
| Ani Pharmaceuticals, INC. | $197.56 | 2022-2023 | Purified Cortrophin Gel |
| Bausch & Lomb Americas INC. | $172.01 | 2023-2025 | Envista Envy, Miebo, Xiidra |
| Merz Pharmaceuticals, LLC | $165.66 | 2022-2025 | Xeomin |
| Galderma Laboratories, L.P. | $150.00 | 2020 | |
| Sun Pharmaceutical Industries INC. | $131.79 | 2020-2025 | Cequa |
| Allergan, INC. | $130.42 | 2019-2021 | |
| Stryker Corporation | $120.80 | 2025 | Medpor Titan, Na |
| Alcon Vision LLC | $97.86 | 2022-2025 | Tryptyr, Rocklatan, Clareon |
| Regeneron Healthcare Solutions, INC. | $81.12 | 2023-2025 | Eylea Hd |
| Abbvie INC. | $78.20 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $69.45 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $58.81 | 2023-2025 | |
| Rayner Intraocular Lenses Limited | $51.84 | 2023 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Harrow Eye, LLC | $46.76 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $46.63 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $40.87 | 2019 | |
| Aerie Pharmaceuticals, INC. | $34.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.34 | 2021-2023 | |
| Apellis Pharmaceuticals, INC. | $26.66 | 2025 | Syfovre |
| Ocular Therapeutix, INC. | $20.19 | 2023 | Dextenza |
| Dompe US, INC. | $19.48 | 2025 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $18.80 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.66 | 2019 | |
| Mallinckrodt Enterprises LLC | $18.30 | 2019 | |
| Thea Pharma INC. | $17.60 | 2024 | Iyuzeh |
| Alimera Sciences, INC. | $17.42 | 2024 | Yutiq, Iluvien |
| Kala Pharmaceuticals, INC. | $15.59 | 2021 | |
| Genentech USA, INC. | $15.43 | 2022 | |
| Oyster Point Pharma, INC. | $15.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Joly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.